• Explore /
  • Poster
  • / Analysis of the kinetics and effects of vemurafenib (V) + cobimetinib (C) on intratumoral and host immunity in patients (pts) with BRAFV600 mutant melanoma (BRAFmM): Implications for combination with immunotherapy.

Analysis of the kinetics and effects of vemurafenib (V) + cobimetinib (C) on intratumoral and host immunity in patients (pts) with BRAFV600 mutant melanoma (BRAFmM): Implications for combination with immunotherapy.

Abstract Poster

Authors

null

Suthee Rapisuwon

Georgetown University, Lombardi Comprehensive Cancer Center, Washington, DC

Suthee Rapisuwon , Craig L. Slingluff Jr., Jennifer Ann Wargo , Ryan J. Sullivan , Benjamin Izar , Ileana S Maudlin , Geoffrey Thomas Gibney , Waddah B. Al-Refaie , Bridget Haley , Michael B. Atkins

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT01813214

Citation

J Clin Oncol 36, 2018 (suppl; abstr 9559)

DOI

10.1200/JCO.2018.36.15_suppl.9559

Abstract #

9559

Poster Bd #

386

Abstract Disclosures

Similar Posters

Poster

2019 ASCO Annual Meeting

Molecular biology and treatment strategies for non-V600 BRAF-mutant NSCLC.

Molecular biology and treatment strategies for non-V600 BRAF-mutant NSCLC.

First Author: Marcelo Vailati Negrao

First Author: Matthew Dankner

First Author: Ryan J. Sullivan

First Author: Melissa K. Yee